Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human-induced pluripotent stem cell cardiomyocytes for risk stratification of patients with LQT syndrome-ready for practice?

Cardiovascular research·2026
Same author

Mechanical load inhibits cancer growth in mouse and human hearts.

Science (New York, N.Y.)·2026
Same author

Models of the human heart for biomedical research: Opportunities and challenges.

Physiological reports·2026
Same author

The conjugation-resistant bile acid norUDCA cures liver fibrosis but impairs systemic energy metabolism.

Molecular metabolism·2026
Same author

Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in <i>LMNA</i> Mutation-Induced Dilated Cardiomyopathy.

Circulation. Heart failure·2026
Same author

Activation of IRF3 in cardiomyocytes impairs mitochondrial oxidative function through PGC-1α inhibition and drives heart failure.

Nature communications·2026

Related Experiment Video

Updated: Apr 11, 2026

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening
10:39

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening

Published on: April 15, 2017

13.8K

Human engineered heart tissue as a model system for drug testing.

Alexandra Eder1, Ingra Vollert1, Arne Hansen1

  • 1Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany; Cardiovascular Research Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Hamburg, Germany.

Advanced Drug Delivery Reviews
|June 1, 2015
PubMed
Summary

Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) show promise for drug safety testing but require maturation. Engineered heart tissue (EHT) improves hiPSC-CM maturity and enables high-content screening for preclinical drug development.

Keywords:
Cardiac safety pharmacologyDrug developmentEngineered heart tissueHuman induced pluripotent stem cell derived cardiomyocytesMaturationScreening assays

More Related Videos

Slicing and Culturing Pig Hearts under Physiological Conditions
07:54

Slicing and Culturing Pig Hearts under Physiological Conditions

Published on: March 20, 2020

18.2K
Designing a Bioreactor to Improve Data Acquisition and Model Throughput of Engineered Cardiac Tissues
12:28

Designing a Bioreactor to Improve Data Acquisition and Model Throughput of Engineered Cardiac Tissues

Published on: June 2, 2023

3.3K

Related Experiment Videos

Last Updated: Apr 11, 2026

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening
10:39

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening

Published on: April 15, 2017

13.8K
Slicing and Culturing Pig Hearts under Physiological Conditions
07:54

Slicing and Culturing Pig Hearts under Physiological Conditions

Published on: March 20, 2020

18.2K
Designing a Bioreactor to Improve Data Acquisition and Model Throughput of Engineered Cardiac Tissues
12:28

Designing a Bioreactor to Improve Data Acquisition and Model Throughput of Engineered Cardiac Tissues

Published on: June 2, 2023

3.3K

Area of Science:

  • Cardiovascular Research
  • Drug Discovery
  • Stem Cell Biology

Background:

  • Current preclinical drug testing models have limitations in predicting human cardiotoxicity.
  • Species-specific differences in cardiomyocyte biology hinder the translation of animal model data.
  • Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) offer a human-specific model but are often immature.

Purpose of the Study:

  • To review the technology of 3D engineered heart tissue (EHT) for culturing hiPSC-CM.
  • To evaluate the potential of EHT-cultured hiPSC-CM for preclinical drug screening.
  • To discuss the advantages and disadvantages of the EHT approach for drug safety pharmacology.

Main Methods:

  • Culturing hiPSC-CM in a 3D engineered heart tissue (EHT) format.
  • Utilizing silicone racks in a 24-well plate for automated, multiplexed readouts.
  • Assessing improved cardiomyocyte maturity and anisotropy in EHT models.
  • High-content readout of contractile function for drug response evaluation.

Main Results:

  • EHT culture enhances hiPSC-CM maturity and structural organization (anisotropy).
  • The 3D EHT format enables automated, high-content screening of drug effects.
  • This approach improves the predictive value of hiPSC-CM for drug safety.

Conclusions:

  • Engineered heart tissue (EHT) represents a significant advancement in maturing hiPSC-CM for drug screening.
  • The EHT technology offers a promising platform for improving preclinical cardiotoxicity assessment.
  • Further development of EHT models can enhance drug discovery and safety pharmacology pipelines.